Event: iwCLL 2023

0:01:59

A strategy for curing CLL, one clone at a time

0:01:56

Resistance to non-covalent BTKi’s

0:02:25

Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial

0:00:45

Key trials in CLL and designing a concept for treatment

0:02:00

Associated toxicities of novel therapies for CLL

0:02:17

The current SoC in Richter’s transformation and the potential role of CAR T-cell therapy

0:01:47

Future research priorities and unmet needs in patients with CLL

0:01:25

Zanubrutinib in patients with CLL intolerant to ibrutinib and acalabrutinib

0:02:43

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax

0:01:09

Sequencing of therapies to improve outcomes of CLL patients

0:01:11

Integrating MRD data into treatment decisions in CLL

0:01:51

Understanding and overcoming resistance mechanisms to novel agents used in CLL

0:03:26

MIRACLE study: using an MRD-guided strategy to direct treatment duration in previously untreated CLL

0:02:12

Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL

0:01:24

Investigating the biology of Richter’s transformation

0:01:31

MAIC of pirtobrutinib vs venetoclax continuous monotherapy in patients with R/R CLL

0:01:48

The OxPLoreD study: T-cell type abundance and gene expression in early lymphoproliferative disorders

0:01:20

Improving outcomes of non-covalent BTKi treatment

0:03:01

METTL3 upregulation leads to aggressive CLL

0:03:04

Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania

0:02:05

In-vivo modeling of CLL and Richter's transformation

0:01:22

PROTACs: potential novel agents for the treatment of CLL

0:02:46

Modeling the tumor microenvironment of CLL in vitro

0:03:32

The use of surrogate endpoints in CLL clinical trials